The Global Arthritic Therapeutic Market size is expected to reach $112.6 billion by 2030, rising at a market growth of 5.1% CAGR during the forecast period.
The osteoarthritis segment encompasses a diverse array of treatment modalities, including pharmacological interventions, non-pharmacological therapies, and surgical interventions. Therefore, the osteoarthritis segment captured $7,913.2 million revenue in the market in 2022. Pharmaceutical companies develop and market a range of medications for osteoarthritis, including analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and viscosupplementation agents, to provide symptom relief and improve joint function.
As the prevalence of arthritis continues to rise globally, there is a growing population of individuals affected by the disease. This expanding patient population creates a larger market for arthritis therapies, including pharmacological interventions, non-pharmacological treatments, surgical procedures, and assistive devices, driving demand for arthritis treatments, and supporting market growth. Therefore, the market is expanding significantly due to the growing prevalence of arthritis.
Additionally, complementary and alternative therapies encompass various treatment modalities, including acupuncture, massage therapy, yoga, tai chi, dietary supplements, herbal remedies, and mind-body techniques. Thus, because of the rising focus on complementary and alternative therapies, the market is anticipated to increase significantly.
However, The high cost of arthritis therapeutics places a substantial financial burden on patients, particularly those without adequate insurance coverage or limited financial resources. The financial burden of arthritis management can contribute to medication rationing, skipping doses, or preceding necessary medical interventions, ultimately compromising treatment efficacy and patient outcomes. Thus, high cost can slow down the growth of the market.
The COVID-19 pandemic disrupted routine healthcare services, including outpatient visits, elective procedures, and non-urgent medical appointments, leading to delays in arthritis diagnosis, treatment initiation, and disease monitoring. The COVID-19 pandemic disrupted global drug supply chains, leading to shortages, stockouts, and delays in the availability of certain arthritic medications, including biologic therapies and specialty drugs. Thus, the COVID-19 pandemic had a moderate effect on the market.
The osteoarthritis segment encompasses a diverse array of treatment modalities, including pharmacological interventions, non-pharmacological therapies, and surgical interventions. Therefore, the osteoarthritis segment captured $7,913.2 million revenue in the market in 2022. Pharmaceutical companies develop and market a range of medications for osteoarthritis, including analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and viscosupplementation agents, to provide symptom relief and improve joint function.
As the prevalence of arthritis continues to rise globally, there is a growing population of individuals affected by the disease. This expanding patient population creates a larger market for arthritis therapies, including pharmacological interventions, non-pharmacological treatments, surgical procedures, and assistive devices, driving demand for arthritis treatments, and supporting market growth. Therefore, the market is expanding significantly due to the growing prevalence of arthritis.
Additionally, complementary and alternative therapies encompass various treatment modalities, including acupuncture, massage therapy, yoga, tai chi, dietary supplements, herbal remedies, and mind-body techniques. Thus, because of the rising focus on complementary and alternative therapies, the market is anticipated to increase significantly.
However, The high cost of arthritis therapeutics places a substantial financial burden on patients, particularly those without adequate insurance coverage or limited financial resources. The financial burden of arthritis management can contribute to medication rationing, skipping doses, or preceding necessary medical interventions, ultimately compromising treatment efficacy and patient outcomes. Thus, high cost can slow down the growth of the market.
The COVID-19 pandemic disrupted routine healthcare services, including outpatient visits, elective procedures, and non-urgent medical appointments, leading to delays in arthritis diagnosis, treatment initiation, and disease monitoring. The COVID-19 pandemic disrupted global drug supply chains, leading to shortages, stockouts, and delays in the availability of certain arthritic medications, including biologic therapies and specialty drugs. Thus, the COVID-19 pandemic had a moderate effect on the market.
By Product Type Analysis
By product type, the market is categorized into non-steroidal anti-inflammatory drugs (NSAIDs), disease modified anti-rheumatoid drugs (DMARDs), biologics, and others. In 2022, the non-steroidal anti-inflammatory drugs (NSAIDs) segment held 38.7% revenue share in the market. NSAIDs are instrumental in managing various symptoms associated with arthritis, including pain, swelling, stiffness, and functional impairment.
By Application Analysis
Based on application, the market is classified into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, and others. The psoriatic arthritis segment acquired 12.9% revenue share in the market in 2022. Psoriatic arthritis represents a significant unmet medical need, as it affects individuals with psoriasis, a common skin condition, and can lead to progressive joint damage, disability, and impaired quality of life if left untreated.By Regional Analysis
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired 23.4% revenue share in the market. Urbanization and lifestyle changes in the Asia Pacific region, including sedentary lifestyles, unhealthy diets, obesity, and physical inactivity, contribute to the rising prevalence of arthritis.Recent Strategies Deployed in the Market
- 2023-Oct: Amgen, Inc. completed the acquisition of Horizon Therapeutics plc, a biopharmaceutical company. Through this acquisition, Horizon will help to further establish Amgen as a leader across a broader range of diseases. Furthermore, the companies will collaborate to serve even more patients worldwide who are suffering from serious illnesses.
- 2022-Oct: Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company. Through this acquisition, Pfizer enhanced its product portfolio of potential calcitonin gene-related peptide (CGRP) receptor antagonists.
- 2022-Mar: Pfizer, Inc. completed the acquisition of Arena Pharmaceuticals, Inc., a clinical-stage company. Under this acquisition, Arena Pharmaceuticals will give Pfizer access to a collection of different and promising experimental treatments in areas like stomach and intestine health, skin conditions, and heart-related issues.
- 2021-Dec: Novartis AG received approval from the US Food and Drug Administration (FDA) for Cosentyx (secukinumab), which is required for the treatment of active enthesitis-related arthritis (ERA) in patients four years and older and active juvenile psoriatic arthritis (JPsA) in patients two years and older. Cosentyx is the first biologic indicated for ERA and the only biologic treatment approved for both ERA and PsA in paediatric patients in the US. The approved paediatric dosing for Cosentyx in children and adolescents is 75 mg (15 kg or more to less than 50 kg) or 150 mg (50 kg or more).
- 2020-Oct: Merck & Co., Inc. came into an agreement with Novartis AG, a Swiss multinational pharmaceutical corporation. Under this agreement, the M6495, an anti-ADAMTS5 Nanobody intended for potential osteoarthritis (OA) therapy, was introduced. The new product is designed to be administered via self-injection under the skin, with the goal of preserving knee joint structural integrity and alleviating pain.
List of Key Companies Profiled
- AbbVie, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- F.Hoffmann-La Roche Ltd.
- Viatris, Inc.
- Bausch Health Companies, Inc.
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Market Report Segmentation
By Application- Rheumatoid Arthritis
- Psoriatic Arthritis
- Osteoarthritis
- Ankylosing Spondylitis
- Others
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Disease Modified Anti-rheumatoid Drugs (DMARDs)
- Biologics
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Global Arthritic Therapeutic Market, by Application
Chapter 6. Global Arthritic Therapeutic Market, by Product Type
Chapter 7. Global Arthritic Therapeutic Market, by Region
Chapter 8. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Viatris, Inc.
- Bausch Health Companies, Inc.
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Methodology
LOADING...
